ESPR Q1 2025 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$577M

Q1 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$65M-52.8% YoY

Gross Profit

$33M51.5% margin

Operating Income

-$22M-34.0% margin

Net Income

-$40M-62.2% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

-6.0%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$324M

Total Liabilities

$750M

Stockholders' Equity

-$426M

Cash & Equivalents

$115M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$65M	$138M	-52.8%
Gross Profit	$33M	$128M	-73.8%
Operating Income	-$22M	$72M	-130.6%
Net Income	-$40M	$61M	-166.3%

Revenue Segments

Product

$35M54%

Collaboration Revenue

$30M46%